Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1652

Current Trends in Gastroenterology and Hepatology

Mini Review(ISSN: 2641-1652)

Potassium-Competitive Acid Blocker: Novel Class of Anti- Acid Drug Volume 2 - Issue 2

Jaeyong Han MD1,2, Seung Hun Lee MD3 and Tong Wang MD1*

  • 1 Department of Cellular and Molecular Physiology, Yale University, New Haven, CT, USA
  • 2 Department of Internal Medicine, Seoul Bon Clinic, Seoul, Korea
  • 3 Department of Internal Medicine, Section of Nephrology, New Haven, USA

Received:March 09, 2019;   Published: March 14, 2019

*Corresponding author:Tong Wang, Department of Cellular and Molecular Physiology, New Haven, USA

DOI: 10.32474/CTGH.2019.02.000131


Abstract PDF

Also view in:


Over the past several decades, great progress has been made on understanding mechanisms of gastric acid secretion for developing new anti-acid drugs. Until now most commonly used anti-acid drugs are histamine-2 receptor antagonists and proton pump inhibitors (PPIs) for patients to control acid related disease. However, several clinical limitations of these drugs had been reported. Recently, a new generation of potassium-competitive acid blockers (P-CABs) were launched for clinical use. It has been shown that these new drugs are more convenient and powerful to treat gastric acid-related diseases. In this article, we briefly reviewed the clinical use of this new anti-acid drug P-CAB.

Keywords:Potassium-competitive Acid Blocker; Potassium channel; H+/K+-ATPase


H+/K+-ATPase (or proton pump), which is expressed in gastric parietal cells, is one of the potassium transporters acting in the last stage involved in gastric acid production and secretion [1]. It functions in the parietal cells that pump out protons into the luminal space of gastric glands to reach a level of one million-fold enrichment of H+ in the gastric juice. At the same time the K+ is absorbed into the cell, which is coupled with K+ recycling by potassium channels [2,3]. The gastric H+/K+-ATPase has a half-life of 50h, hence about 25% of proton pumps are newly synthesized per day, at a rate of about 1% per hour [4]. The importance of K+ in the production of gastric acid makes its regulation a potential target for treatment [5].


Clinical Limitation of PPIS

Since proton pump inhibitors (PPI) were first discovered in 1981, several types of PPIs have been used in the treatment of acid–related diseases such as peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD) for the past 30 years [6,7]. PPIs bind irreversibly to the gastric H+/K+-ATPase and inhibit potassium recycling, thus this inhibition is long-lasting and dose not show rapid tolerance which allows acid rebound following withdrawal that had also appeared in histamine-2 receptor antagonists. However, they have short plasma half-life of about 2hrs and are rapidly degraded in vivo and bind only to activated proton pump. Therefore, these drugs require daily dosing of 4 to 5 days to achieve the maximum efficacy [8]. There were many cases in which they were unable to demonstrate sufficient effect when the medication time was not properly maintained before a meal. PPIs binding only to active form of proton pump have been known clinically to be limited to increase the pH to only around 4.0. Meanwhile, it has been reported that increasing the pH to 6.0 instead of to 4.0 for Helicobacter pylori eradication is more effective [9].

Novel P-CAB Class Drugs

Potassium-competitive acid blocker (P-CAB) reversibly inhibits acid secretion by competing with the potassium ion on the luminal surface of the gastric wall H+/K+-ATPase. The first developed compound was SCH28080 in 1982 [10]. Animal and early clinical studies have shown that P-CAB is highly selective for gastric H+/K+- ATPase and inhibits gastric acid secretion with fast onset of action [11]. SCH28080 has been used extensively to reveal the mechanism of proton pump inhibition. However, the first-generation drugs did not come out due to its brief action time and hepatotoxicity [12]. The new generation of P-CAB drugs, Vonoprazan (TAK-438) and Tegoprazan (CJ-12420) that overcome these shortcomings were recently launched [13,14]. These drugs block not only the proton pump in the active form but also the inactive form proton pump, thereby effectively increasing intraluminal pH to 6.0. In the case of vonoprazan, 98% of H. pylori eradication treatment results were reported [15]. The comparisons between PPI and P-CAB products are shown below in the Table 1.

Table 1: The differences between PPIs and P-CABs.



Advantages of P-CAB versus PPI include the rapidly and more potent acid suppression, stable in acid condition, meal independent, able to elevate pH to 6.0 and better treatment of PUD, GERD, and H. pylori eradication. It is predicted that P-CAB drugs will be widely used as next generation drugs overcoming the shortcomings of existing PPI drugs.


  1. Ganser AL, Forte JG (1973) K+ -stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim Biophys Acta 307: 169-180.
  2. Heitzmann D, Warth R (2007) No potassium, no acid: K+ channels and gastric acid secretion. Physiology (Bethesda) 22: 335-341.
  3. Han J, Lee SH, Giebisch G, Wang T (2016) Potassium Channelopathies and Gastrointestinal Ulceration. Gut Liver 10: 881-889.
  4. Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G (1995) Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 109: 1134-1141.
  5. Geibel JP (2005) Role of potassium in acid secretion. World J Gastroenterol 11: 5259-5265.
  6. Fellenius E, Berglindh T, Sachs G (1981) Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase. Nature 290: 159-161.
  7. Sachs G, Shin JM, Hunt R (2010) Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 12: 437-447.
  8. Tytgat GN (2001) Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 13 Suppl 1: S29-33.
  9. Sugimoto M, Furuta T, Shirai N (2007) Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12: 317-323.
  10. Ene MD, Khan-Daneshmend T, Roberts CJ (1982) A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br J Pharmacol 76: 389-391.
  11. Wurst W, Hartmann M (1996) Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med 69: 233-243.
  12. Dent J, Kahrilas PJ, Hatlebakk J (2008) A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 103: 20-26.
  13. Garnock-Jones KP (2015) Vonoprazan: first global approval. Drugs 75: 439-443.
  14. Lee KJ, Son BK, Kim GH (2019) Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther, p. 1‐9.
  15. Murakami K, Sakurai Y, Shiino M, Funao N (2016) A novel potassiumcompetitive acid blocker, as a component of first-line and secondline triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446.